FILTER
đŸŠē

D-Dopa TAB Pack Image

Levodopa + Carbidopa

100 mg+10 mg

Drug International Ltd.

Unit Price: ā§ŗ 7.00 (3 x 10: ā§ŗ 210.00)

Also available as:

100 mg+10 mg mg

Indications

This combination tablet is indicated for the treatment of Parkinson's disease and syndrome. It is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. This tablet is frequently helpful in the management of tremor, dysphagia, sialorrhea and postural instability associated with Parkinson's disease and syndrome. Levodopa plus carbidopa before physiotherapy increases motor recovery after stroke.

* āϰ⧇āϜāĻŋāĻ¸ā§āϟāĻžāĻ°ā§āĻĄ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ āĻ”āώāϧ āϏ⧇āĻŦāύ āĻ•āϰ⧁āύ

Dosage & Administration

Levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and is converted to dopamine in the brain. Carbidopa is a dopa decarboxylase (DDC) inhibitor which reduces the peripheral metabolism of Levodopa to dopamine, and thus, more Levodopa becomes available to the brain.

Interaction

Levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and is converted to dopamine in the brain. Carbidopa is a dopa decarboxylase (DDC) inhibitor which reduces the peripheral metabolism of Levodopa to dopamine, and thus, more Levodopa becomes available to the brain.

Contraindications

Levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and is converted to dopamine in the brain. Carbidopa is a dopa decarboxylase (DDC) inhibitor which reduces the peripheral metabolism of Levodopa to dopamine, and thus, more Levodopa becomes available to the brain.

Side Effects

Levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and is converted to dopamine in the brain. Carbidopa is a dopa decarboxylase (DDC) inhibitor which reduces the peripheral metabolism of Levodopa to dopamine, and thus, more Levodopa becomes available to the brain.

Pregnancy & Lactation

Levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and is converted to dopamine in the brain. Carbidopa is a dopa decarboxylase (DDC) inhibitor which reduces the peripheral metabolism of Levodopa to dopamine, and thus, more Levodopa becomes available to the brain.

Precautions & Warnings

Levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and is converted to dopamine in the brain. Carbidopa is a dopa decarboxylase (DDC) inhibitor which reduces the peripheral metabolism of Levodopa to dopamine, and thus, more Levodopa becomes available to the brain.

Therapeutic class

Antiparkinson drugs

Storage conditions

Store in a cool and dry place, protected from light.

Use in Special Populations

Levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and is converted to dopamine in the brain. Carbidopa is a dopa decarboxylase (DDC) inhibitor which reduces the peripheral metabolism of Levodopa to dopamine, and thus, more Levodopa becomes available to the brain.